Physician profile
Amitabh Singh
NPI 1053843540
$14,249.75
in general payments reported to CMS, 2019-2025
54 companies · $4,018 in 2025
The $4,018 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $1,285 · 2023: $3,707 · 2024: $4,450 · 2025: $4,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $52.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,122.26 |
| Education | $52.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,336.13 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,754.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $904.04 | 2021-2025 | Tezspire, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $797.22 | 2022-2025 | Xarelto, Spravato |
| Daiichi Sankyo INC. | $745.84 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $577.57 | 2021-2025 | |
| Gilead Sciences, INC. | $521.14 | 2022-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.43 | 2022-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $439.65 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Pfizer INC. | $382.86 | 2023-2025 | |
| Amgen INC. | $370.85 | 2023-2025 | Otezla, Repatha, Repatha |
| Braeburn INC. | $345.60 | 2024-2025 | Brixadi |
| Axsome Therapeutics, INC. | $330.05 | 2024-2025 | Auvelity |
| Medtronic, INC. | $327.50 | 2023-2024 | Venaseal, Minimed 780g, Minimed 770g |
| Glaxosmithkline, LLC. | $294.30 | 2023-2025 | Arexvy, Nucala, Trelegy Ellipta |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $289.10 | 2023-2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $253.88 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $248.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.03 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $204.77 | 2022-2024 | Dificid, Delstrigo, Pifeltro |
| Lilly USA, LLC | $202.45 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Vanda Pharmaceuticals INC. | $189.32 | 2024-2025 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $183.16 | 2025 | Axios |
| Corcept Therapeutics | $175.86 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $164.23 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Phathom Pharmaceuticals, INC. | $147.92 | 2025 | Voquezna |
| Eisai INC. | $125.00 | 2025 | |
| Stryker Corporation | $124.80 | 2024 | Infinity Adaptis |
| Genzyme Corporation | $103.56 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.53 | 2022 | |
| Optinose US, INC. | $97.93 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $96.88 | 2024 | Uptravi, Opsumit |
| Janssen Biotech, INC. | $94.10 | 2022-2025 | Tremfya |
| Abbott Laboratories | $71.28 | 2024 | Jot Dx |
| Nestle Healthcare Nutrition INC. | $56.69 | 2023 | |
| Kyowa Kirin, INC. | $53.21 | 2023-2024 | Crysvita |
| Viiv Healthcare Company | $43.36 | 2023-2024 | Apretude, Dovato |
| Insmed, INC. | $43.17 | 2023-2024 | Arikayce |
| Theratechnologies INC. | $42.22 | 2023 | Trogarzo, Egrifta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.10 | 2022 | |
| Sanofi Pasteur INC. | $36.23 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $32.53 | 2025 | Jornay Pm |
| Alk-Abello, INC | $30.25 | 2023-2025 | Odactra, Grastek |
| Almatica Pharma LLC | $30.15 | 2024 | Teriparatide |
| Vertex Pharmaceuticals Incorporated | $22.48 | 2025 | |
| Neurocrine Biosciences, INC. | $21.89 | 2025 | |
| Shield Therapeutics INC | $17.90 | 2025 | |
| Astellas Pharma US INC | $17.46 | 2023 | Veozah |
| Aimmune Therapeutics, INC. | $16.16 | 2025 | Zenpep |
| Cequr Corporation | $15.81 | 2025 | Cequr Simplicity |
| Scilex Pharmaceuticals INC. | $15.68 | 2022 | |
| Redhill Biopharma INC. | $14.37 | 2022 | |
| Mylan Specialty L.P. | $14.22 | 2024 | Yupelri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitabh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.